1. Introduction {#sec1}
===============

It is now widely recognized that diabetes mellitus (DM) is associated with an increased risk of fractures, which seems to be dependent on mechanisms at least partly differing from those associated with senile or postmenopausal osteoporosis \[[@B1]\]. A meta-analysis of 16 studies showed a relative risk for hip fractures of 6.94 in type 1 DM (T1DM) and 1.38 in type 2 DM (T2DM) compared to subjects without DM \[[@B2]\]. Interestingly, bone mineral density (BMD), the strongest predictor of fractures in subjects with osteoporosis \[[@B3]\], was found to be reduced in patients with T1DM in most, but not all studies, whereas cross-sectional surveys in subjects with T2DM reported normal or even increased BMD, despite the overall increase in fracture risk \[[@B2]\]. Moreover, increased fracture risk in T2DM patients remained after adjustment for BMD \[[@B4]--[@B6]\] and also for falls \[[@B4], [@B6], [@B7]\], which are more frequent in older individuals with T2DM than in their nondiabetic counterparts \[[@B8]\]. While the lower fracture risk in T2DM versus T1DM may be explained by the normal-to-increased bone mass, the apparent discrepancy between preserved BMD and increased fracture risk in individuals with T2DM and the higher fracture risk than that estimated from BMD variation in subjects with T1DM have prompted the hypothesis that DM patients have reduced bone quality \[[@B1], [@B2]\].

Bone quality is determined by (a) bone architecture, including geometry (macroarchitecture) and microarchitecture, and (b) material properties, including mineralization and collagen cross-links, which in turn are influenced by bone turnover as well as by accumulation of microdamage and microstructural discontinuities such as microporosity and lamellar boundaries \[[@B9]\]. Several factors have been claimed to affect bone quality (and mass) in DM, mainly by reducing bone turnover \[[@B10]\]. The advanced glycation endproducts (AGEs) cause the formation of collagen cross-links, which negatively correlate with material properties, in addition to adversely affecting bone metabolism via receptor-mediated mechanisms \[[@B11]\]. Moreover, the long-term, microvascular, and macrovascular complications have been hypothesized to contribute to impaired bone turnover in T1DM and T2DM patients, consistent with the role of vessels \[[@B12]\] and nerves \[[@B13]\] in bone metabolism, and also to favor falls and injury in a fall \[[@B14]\]. In fact, diabetic peripheral neuropathy (DPN) is also an independent risk factor for reduced BMD in the affected limbs \[[@B15]\] and increases the risk of falls by affecting balance and gait \[[@B16]\], thus leading to increased fracture risk \[[@B17]\]. Likewise, the reduction of muscle strength, mass, and quality associated with DM \[[@B18]\] cause not only reduced mechanical strain on the skeleton resulting in reduced bone mass, according to the mechanostat theory \[[@B19]\], but also poor physical performance and reduced mobility favoring falls \[[@B20]\]. In contrast, the impact of hyperinsulinemia and increased body mass index (BMI) associated with T2DM is controversial. On the one hand, they may favor bone formation through direct anabolic effects \[[@B21]\] and increased mechanical load \[[@B22]\], respectively. On the other hand, the low-grade inflammation accompanying insulin resistance can exert detrimental effects on the skeleton \[[@B23]\] and insulin resistance may suppress bone turnover independently of adiposity \[[@B24]\].

Quantitative ultrasound (QUS), which is performed mainly at the heel, provides an estimate of BMD, thus reflecting bone mass \[[@B25]\]. Assessment of estimated BMD (eBMD) by QUS confirmed the increase in BMD detected by dual-energy X-ray absorptiometry (DXA) in patients with T2DM \[[@B26]\]. In older women with T2DM, QUS predicted fracture risk better than DXA \[[@B26]\], though, just like DXA-derived BMD, it failed to identify T2DM subjects with vertebral fractures \[[@B27]\]. In addition, QUS evaluates parameters of bone quality, including microarchitecture and material properties \[[@B28], [@B29]\].

This study was aimed at assessing the correlates of calcaneal QUS parameters in subjects with T1DM and T2DM, encompassing various degrees of micro- and macrovascular complications and a wide-range of peripheral nerve function.

2. Subjects and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

In this cross-sectional analysis, we used the data collected at the baseline visit for the Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes (SAMBA), an observational, prospective cohort study on the independent predictors of loss of muscle and bone strength in patients with T1DM and T2DM. The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. The research protocol was approved by the locally appointed ethics committee, and participants gave written informed consent.

The SAMBA cohort included 400 patients, 80 with T1DM and 320 with T2DM, who attended consecutively an outpatient diabetes clinics for the screening of complications in years 2008--2011. Patients who were unable to correctly perform the test procedures were excluded from the study \[[@B30]\].

2.2. Measurements {#sec2.2}
-----------------

### 2.2.1. Calcaneal QUS {#sec2.2.1}

QUS measurements were performed at the heel using the Sahara® Clinical Bone Sonometer (Hologic Inc., Waltham, MA, USA).

Broadband ultrasound attenuation (BUA; in dB/MHz) and speed of sound (SOS; in m/s) were measured, and the quantitative ultrasound index (QUI) or stiffness index (SI) was calculated from them and expressed as absolute values and T- and Z-scores. In turn, eBMD (g/cm^2^) was derived from QUI \[[@B25], [@B26]\] and expressed as absolute values and T- and Z-scores.

### 2.2.2. Cardiovascular Risk Factors {#sec2.2.2}

All patients underwent a structured interview in order to collect the following information: demographics, lifestyle habits, known DM duration, and current treatments.

Physical activity (PA) level was assessed using the Minnesota Leisure-Time PA questionnaire \[[@B30]\]. Patients were then classified as sedentary (i.e., ≥8 hours/day spent in any waking behavior characterized by an energy expenditure ≤ 1.5 metabolic equivalents (METs) while in a sitting or reclining posture), physically inactive (i.e., not engaged in any physical activity during the week), or physically active (i.e., low PA \[\<3.5 METs·h^−1^·week^−1^\], moderate PA \[3.5--10 METs·h^−1^·week^−1^\], or high PA \[\>10 METs·h^−1^·week^−1^\]). Cardiorespiratory fitness was assessed by measuring maximal oxygen consumption (VO~2max~) at the treadmill, using a modified Balke and Ware protocol, with direct measurement of oxygen consumption using the gas exchange analyzer (FitMate, Cosmed, Rome, Italy). Muscle strength was assessed in isometric conditions by means of a Digimax electronic dynamometer (Mechatronic GmbH, Germany), as previously described \[[@B30]\].

BMI was calculated from body weight and height, waist circumference was measured at the umbilicus, and fat mass and fat-free mass were assessed by body impedance (Tanita BF664, Vernon Hills, IL, USA). Blood pressure (BP) was measured with a mercury sphygmomanometer with the patients seated with the arm at the heart level. Hypertension was defined by systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 and/or antihypertensive treatment.

Hemoglobin- (Hb-) A~1c~ was assessed by a DCCT-aligned high-performance liquid chromatography method (Adams TMA1C HA-8160, Menarini Diagnostics, Florence, Italy). Fasting glucose, triglycerides, total and HDL cholesterol, nitrogen, and uric acid were measured by standard analytical methods using the VITROS 5.1 FS Chemistry System (Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA), and LDL cholesterol was calculated by the Friedewald formula.

### 2.2.3. Complications {#sec2.2.3}

Prevalent cardiovascular disease (CVD) was assessed from medical history by recording previous documented major acute CVD events, including myocardial infarction, stroke, foot ulcer, gangrene and amputation, and revascularization procedures \[[@B31]\]. In addition, carotid intima-media thickness (IMT) and ankle-brachial index (ABI) were assessed as surrogate measures of diabetic macroangiopathy by color-coded duplex sonography (Agilent HP ImagePoint HX, Hewlett Packard, Rome, Italy) and a mercury sphygmomanometer plus a handheld continuous wave Doppler device (Super Doppler 2, Huntleigh Healthcare, Lewis Center, OH), respectively.

Diabetic nephropathy was evaluated by assessing serum creatinine and albuminuria. Serum creatinine was measured by the modified Jaffe method, and estimated glomerular filtration rate (eGFR) was calculated by the chronic kidney disease epidemiology collaboration (CKD-EPI) equation (<http://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr>). Albuminuria was assessed as albumin : creatinine ratio (ACR) by measuring albumin and creatinine concentration by immunonephelometry and the modified Jaffe method, respectively, in first-morning, urine samples. Patients were then assigned to one of the following categories of eGFR (ml/min/1.73 m^2^): 1 (≥90), 2 (60--89), 3a (45--59), 3b (30--44), 4 (15--29), and 5 (\<15), and albuminuria (mg/g): normoalbuminuria (\<30), including normal (\<10) and low (\<10--29) albuminuria, microalbuminuria (30--299), and macroalbuminuria (≥300) \[[@B32]\]. As previously reported \[[@B33]\], patients were classified according to the National Kidney Foundation\'s Kidney Disease Outcomes Quality Initiative as having no CKD, albuminuria alone (stages 1-2 CKD), reduced eGFR alone (stage ≥ 3 CKD without albuminuria), or both (stage ≥ 3 CKD with albuminuria).

Diabetic retinopathy (DR) was evaluated by fundus examination in mydriasis. Patients were classified into the following categories: absent DR, mild, moderate or severe nonproliferative DR, proliferative DR, or maculopathy. For further analysis, patients with mild or moderate nonproliferative DR were classified as having nonadvanced DR, whereas those with severe nonproliferative DR, proliferative DR, maculopathy, or blindness were grouped into the advanced, sight-threatening DR category \[[@B34]\].

Definition of DPN was based on symptoms, signs, and neuroelectrophysiological abnormalities according to the Toronto Diabetic Neuropathy Expert Group and further classified in classical symmetrical polyneuropathy, focal or multifocal neuropathy, or DM-associated neuropathy such as chronic inflammatory demyelinating polyneuropathy \[[@B35]\]. Symptoms and signs of DPN were assessed using the Michigan neuropathy screening instrument (MNSI) comprising a 15-item self-administered questionnaire and a lower extremity examination that includes foot inspection, assessment of vibration perception threshold (VPT) at hallux and ankle reflexes, and monofilament testing (<http://www.med.umich.edu/borc/profs/documents/svi/MNSI_patient.pdf>). The VPT in the left and right malleolus and hallux was assessed by the use of both a diapason and a biothesiometer (Horwell, Nottingham, UK). The distal latencies, amplitudes, and conduction velocities of the peroneal motor nerve (PMN) and sural sensory nerve (SSN) were measured bilaterally by electromyography (EMG), using a Medelec MS 928 Neurostar (Oxford Instruments Medical, Old Woking, UK), and results were compared with age-related reference values \[[@B36]\]. Patients were then stratified for severity of DPN using an arbitrary score calculated as the sum of the individual scores for symptoms (0 to 13, based on the MNSI questionnaire, not considering answers to questions 4 and 10), signs (0 to 10, based on the MNSI lower extremity examination), and EMG data (0 to 12, based on distal latencies, amplitudes, and conduction velocities of sural and peroneal nerves of the two legs).

Autonomic function was assessed by resting heart rate (HR), as a surrogate index, and cardiovascular autonomic reflex tests (CARTs) \[[@B37]\], that is, HR response to deep breathing (beat-to-beat variation and expiration-to-inspiration (EI) ratio), cough test (CT ratio), and standing (30 : 15 ratio), and systolic BP response to standing (supine-standing BP). According to age-related reference values \[[@B38]\], each test was scored as follows: 0 = normal; 1 = borderline, and 2 = abnormal. Subjects were then stratified for cardiac autonomic neuropathy (CAN) based on the sum of the scores assigned to each CART (CAN score).

Maximal voluntary contractions (MVCs) were performed at the shoulder press (Technogym, Gambettola, Italy) along the sagittal plan, with a 45° and 90° angle at the elbow and between the upper arm and the trunk, respectively, for the upper body, and at the leg extension machine (Technogym), with a 90° angle at the knee and the hip, for the lower body \[[@B30]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

Data are expressed as mean ± SD, for continuous variables, and number of cases and percentages for categorical variables. Patients were stratified by age, gender, type of diabetes, PA level, complications, and treatments, and QUS values were compared using the following statistical tests: the Student *t*-test for parametric or the corresponding Mann--Whitney *U* test for nonparametric continuous variables and the *χ*^2^ test for categorical variables.

Univariate analysis of correlations between QUS parameters and the variables tested was performed using Spearman\'s rho. Then, linear regression analyses with stepwise variable selection were applied to assess independent correlates of QUS parameters. Covariates were age, gender, PA level, type and duration of DM, HbA~1c~, BMI (or fat mass and fat-free mass or height and weight), muscle strength, and Vo~2max~ plus surrogate measures of complications (model 1) or the presence/absence of CVD, DR and CKD and DPN and CAN scores (model 2). The analyses were conducted both in the whole cohort and separately in T1DM and T2DM patients.

3. Results {#sec3}
==========

The clinical characteristics of study subjects are reported in [Table 1](#tab1){ref-type="table"}. Males were more frequently former or current smokers and physically active and had higher VO~2max~ (only T2DM), muscle strength, fat-free mass, waist circumference, and lower BMI, fat mass, and HDL cholesterol, as compared with females. While no gender difference was observed in the prevalence of nephropathy, retinopathy, and neuropathy (though there was a significantly different distribution across CKD phenotypes and categories of somatic neuropathy), CVD was more frequent in males than in females.

As previously reported \[[@B30]\], patients with T2DM from the SAMBA cohort had older age, shorter DM duration, lower PA level, VO~2max~, and upper and lower body strength, as compared with subjects with T1DM. In addition, T2DM patients had lower HbA~1c~, total and HDL cholesterol, eGFR, and ABI, and higher BMI, fat mass, fat-free mass, waist circumference, triglycerides, systolic and diastolic BP, uric acid, nitrogen, ACR, and IMT. Prevalence of CVD and CKD was higher in T2DM patients, whereas retinopathy and somatic neuropathy were more frequent in T1DM subjects (Supplementary Table 1 available online at <https://doi.org/10.1155/2017/4749619>).

All QUS parameters were higher in males than in females but did not differ between T1DM and T2DM patients, except for QUI- and eBMD-derived Z-scores, which were similar in women and men and lower in individuals with T1DM than in those with T2DM ([Table 2](#tab2){ref-type="table"}). All QUS parameters, except SOS, decreased significantly with age quartiles (not shown), whereas they increased significantly when stratified according to BMI categories (Supplementary Table 2). In addition, there was a nonsignificant trend towards an increase in BUA, SOS, QUI, and eBMD values with increasing ACR and a significant decrease with decreasing eGFR and increasing severity of DR, DPN, and CAN, but not CVD (data not shown).

At univariate analysis, QUS parameters were strongly associated between each other and with upper and lower body strength, cardiorespiratory fitness, BMI, fat-free mass, waist circumference, triglycerides (except SOS), uric acid, and, inversely, age and HDL cholesterol, but not total and LDL cholesterol, BP, and nitrogen, whereas HbA~1c~ correlated with SOS and DM duration with BUA and QUI only. Among measures of complications, eGFR, albuminuria, ABI, PMN amplitude, SSN distal latency and amplitude, and HR response to cough test and standing correlated with some or all QUS parameters ([Table 3](#tab3){ref-type="table"}). When patients were analyzed separately according to the type of DM, QUS parameters were found to correlate significantly with age, muscle strength, fat-free mass, eGFR, SSN amplitude, and HR response to cough test and standing in T1DM patients and with age, muscle strength, BMI, fat-free mass, waist circumference, HbA~1c~, triglycerides, HDL cholesterol, uric acid, serum creatinine, albuminuria, ABI, SSN amplitude, and HR response to standing, in T2DM patients (not shown).

Multivariate analysis revealed that BUA, SOS, QUI, and eBMD were independently associated with age, male gender, BMI, HbA~1c~ (for SOS and eBMD only), and the following somatic and autonomic nerve function parameters (model 1): PMN and SSN amplitude, VPT hallux (for BUA and eBMD only), HR response to cough test (CT ratio, for eBMD only) and standing (30 : 15, for QUI and eBMD only), and, inversely, resting HR (for SOS and eBMD only). Conversely, the type and duration of DM, muscle strength, Vo~2max~, eGFR, carotid IMT, ABI, and CARTs did not enter the model. In patients with T1DM, age, male gender, BMI, PMN and SSN amplitude, VTP allux, and HR response to cough test and standing (for eBMD only), but not HbA~1c~ and resting HR, were independently associated with QUS measures. In individuals with T2DM, correlates of QUS parameters were similar, except for HbA~1c~ and resting HR, which were significantly associated with QUS measures, VPT hallux and HR response to standing, which were not, and HR response to cough test, which was independently associated with SOS instead of eBMD ([Table 4](#tab4){ref-type="table"}). When fat mass and fat-free mass were included in the model in place of BMI, only the former remained as an independent correlate of QUS parameters, either in the whole cohort or in individuals with T1DM or T2DM (not shown). When substituting height and weight for BMI, only weight was an independent correlate of QUS measures (not shown). The presence/absence of CVD, DR and CKD and DPN and CAN scores, when substituted for individual measures of complications, did not enter the model, except for DPN score when the analysis was conducted only in patients with T1DM (model 2, data not shown).

4. Discussion {#sec4}
=============

This study provides new information on the correlates of QUS parameters in subjects with DM by showing an independent association with age, male gender, HbA~1c~, BMI, and several measures of complications, particularly of DPN and CAN.

While, as expected, values of BUA, SOS, QUI, and eBMD were higher in males than in females and decreased with increasing age; they were similar in patients with T1DM and T2DM. This somewhat surprising finding might be due to the fact that T2DM subjects, though older, had shorter DM duration than those with T1DM, in addition to reflecting the reduced bone mass observed in T1DM, but not T2DM individuals \[[@B2]\]. Also, correlates of QUS parameters were quite similar in patients with T1DM and T2DM, though there were a few differences (e.g., weaker or no association with BMI and HbA~1c~ and stronger association with surrogate measures of peripheral nerve dysfunction in T1DM) which might reflect the differences in bone microarchitecture detected in T1DM (involvement of both trabecular and cortical compartments) \[[@B39]\] versus T2DM (alteration of the cortical compartment only) \[[@B40]\].

The strong association between BMI and QUS parameters is consistent with a large body of evidence showing that DXA-derived BMD is positively related to BMI in the general population \[[@B41]\] and in diabetic patients \[[@B2], [@B42]\], an effect likely mediated by mechanical loading on bone \[[@B22]\], and inversely related to fracture risk \[[@B43]\], though this relation varies according to the fracture site \[[@B44]\]. Indeed, the results of a large meta-analysis have indicated that the relationship between BMI and fracture risk is significantly modified by the interaction between BMI and BMD \[[@B45]\] and a recent study has found that the majority of BMI effect on fracture risk is not direct but rather mediated by femoral neck BMD \[[@B46]\]. Our findings are also consistent with the correlation between BMI and QUS parameters observed in previous reports \[[@B47]--[@B49]\], though other studies failed to detect an association of SOS \[[@B50]\] or all three QUS measures \[[@B51]\] with BMI.

The observation that QUS parameters were positively related also to waist circumference, fat mass, triglycerides and, inversely, HDL cholesterol, but not mass free-mass (except than in univariate analysis), seems to suggest that adiposity, rather than lean mass, is protective for the skeleton. Though fat mass and lean mass both cause mechanical loading \[[@B52]\], the relative effect of these two determinants of body composition on BMD still remains controversial \[[@B53]\]. Our results seem to be at odds with several studies showing that lean mass, but not fat mass, is positively associated with BMD in men \[[@B54]\], women \[[@B55]\], and both \[[@B56]\]. However, a recent meta-analysis showed that the overall impact of lean mass on femoral neck BMD is higher than that of fat mass and that this is the case in men and premenopausal women, whereas in postmenopausal women the effects of lean mass and fat mass are similar \[[@B57]\]. In addition, our findings do not support a detrimental effect of adiposity on bone health through the associated inflammation \[[@B23]\], though inflammatory markers were not assessed in our study.

Another important observation of this study is the association of QUS parameters with measures of peripheral nerve dysfunction, both somatic and autonomic, including PMN and SSN amplitude, VPT, HR response to cough test and standing, and resting HR. Though the latter parameter is not a specific index of CAN, association with QUS measures was independent of several factors which are known to influence HR, such as BMI, PA level, and VO~2max~. The finding that QUS parameters were associated with peripheral nerve function is in agreement with a previous report from the Health, Aging, and Body Composition Study, showing that peripheral nerve dysfunction was related to lower hip BMD and calcaneal QUS in older adults \[[@B58]\]. It is also in keeping with the higher prevalence of neuropathy (52% versus 22%) in subjects with low versus normal BMD \[[@B59]\] and with the independent association of neuropathy with reduced BMD in the affected limbs as well as elsewhere \[[@B15]\] in patients with T1DM. Thus, our data strongly support the concept that DPN may contribute to bone abnormalities and increased fracturative risk in diabetes.

Strengths of the study are the numerous risk factors and measures of complications considered as potential correlates of QUS parameters. Limitations include the cross-sectional design of the study and the relatively low number of patients with T1DM. Moreover, our work might be limited by the lack of a control group, though the comparison with healthy subjects was beyond the scope of our investigation, which was aimed at identifying QUS correlates in diabetic subjects with various degrees of complications.

5. Conclusions {#sec5}
==============

In conclusion, our data indicate that peripheral nerve dysfunction, both somatic and autonomic, is associated with worse QUS parameters, thus suggesting that this complication may contribute to increased fracture risk in diabetes, possibly by impairing bone quality. Conversely, the positive relation of QUS measures with adiposity needs further investigation.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplemental Table 1. Prevalence of complications according to type of DM. Supplemental Table 2. QUS values of study subjects according to the BMI category. The Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes (SAMBA) Investigators.
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###### 

Clinical characteristics of study subjects, overall and by gender.

                                            All            Females          Males            *P*
  ----------------------------------------- -------------- ---------------- ---------------- ----------
  *N* (%)                                   400 (100.0)    172 (43.0)       228 (57.0)       
  T1DM, *n* (%)                             80 (20.0)      42 (24.4)        38 (16.7)        0.055
  Age, years                                61.9 ± 13.6    63.0 ± 13.8      61.1 ± 13.4      0.155
  Smoking, *n* (%)                                                                           \<0.001
   Never                                    237 (59.2)     132 (76.7)       105 (46.1)       
   Former                                   105 (26.3)     22 (12.8)        83 (36.4)        
   Current                                  58 (14.5)      18 (10.5)        40 (17.5)        
  Alcohol intake, *n* (%)                                                                    \<0.001
   No                                       220 (55.0)     133 (77.3)       87 (38.2)        
   Low                                      130 (32.5)     39 (22.7)        91 (39.9)        
   Moderate                                 42 (10.5)      0 (0.0)          42 (18.4)        
   High                                     8 (2.0)        0 (0)            8 (3.5)          
  PA, *n* (%)                                                                                \<0.001
   Sedentary                                73 (18.2)      40 (23.3)        33 (14.5)        
   Inactive                                 130 (32.5)     69 (40.1)        61 (26.7)        
   Active                                                                                    
    Low PA                                  84 (21.0)      31 (18.0)        53 (23.3)        
    Moderate PA                             77 (19.3)      23 (13.4)        54 (23.7)        
    High PA                                 36 (9.0)       9 (5.2)          27 (11.8)        
  Upper body muscle strength, *N*           221.7 ± 92.7   157.3 ± 49.1     270.1 ± 88.2     \<0.001
  Lower body muscle strength, *N*           135.5 ± 62.8   95.7 ± 39.4      164.8 ± 60.7     \<0.001
  VO~2max~, ml/min/kg                       35.3 ± 12.1    33.3 ± 12.6      36.0 ± 11.8      0.182
  Family history of DM, *n* (%)             173 (43.3)     71 (41.3)        102 (44.7)       0.490
  Duration of DM, years                     15.6 ± 10.0    16.7 ± 10.3      14.7 ± 9.7       0.048
  HbA~1c~, %                                7.15 ± 1.44    7.24 ± 1.41      7.09 ± 1.46      0.313
  Glucose, mmol/l                           8.59 ± 3.51    8.39 ± 3.35      8.74 ± 3.63      0.323
  BMI, kg/m^2^                              28.8 ± 5.7     29.57 ± 6.83     28.23 ± 4.62     0.020
  Fat mass, %                               29.6 ± 10.0    37.00 ± 7.35     24.09 ± 7.86     \<0.001
  Fat free mass, kg                         55.2 ± 11.2    45.50 ± 6.66     62.44 ± 7.95     \<0.001
  Waist circumference, cm                   97.5 ± 13.9    94.16 ± 14.57    100.07 ± 12.90   \<0.001
  Triglycerides, mmol/l                     1.65 ± 1.06    1.90 ± 0.63      1.99 ± 0.70      0.016
  Total cholesterol, mmol/l                 4.77 ± 0.99    4.98 ± 0.95      4.61 ± 0.99      \<0.001
  HDL cholesterol, mmol/l                   1.28 ± 0.37    1.43 ± 0.37      1.16 ± 0.32      \<0.001
  LDL cholesterol, mmol/l                   2.82 ± 0.98    2.91 ± 0.90      2.75 ± 1.04      0.097
  SBP, mmHg                                 135.0 ± 17.2   137.35 ± 18.58   133.22 ± 15.81   0.017
  DBP, mmHg                                 78.7 ± 8.9     78.95 ± 9.77     78.51 ± 8.23     0.622
  Carotid IMT, mm                           1.01 ± 0.16    0.98 ± 0.17      1.02 ± 0.16      0.025
  ABI                                       0.89 ± 0.15    0.87 ± 0.15      0.91 ± 0.15      0.019
  Uric acid, *μ*mol/l                       294.1 ± 99.7   267.1 ± 101.6    312.7 ± 93.9     \<0.001
  Plasma nitrogen, mmol/l                   16.9 ± 7.1     17.2 ± 7.7       16.6 ± 6.5       0.448
  Serum creatinine, *μ*mol/l                99.3 ± 35.1    89.7 ± 30.5      106.6 ± 36.6     \<0.001
  eGFR, ml/min/1.73 m^2^                    68.3 ± 20.2    65.1 ± 20.0      70.7 ± 20.1      0.006
  ACR, mg/g                                 58.6 ± 65.5    56.1 ± 79.9      60.5 ± 52.2      0.507
  PMN distal latency, m/s                   4.98 ± 0.65    4.80 ± 0.58      5.12 ± 0.67      \<0.001
  PMN amplitude, mV                         3.57 ± 1.35    3.62 ± 1.25      3.53 ± 1.42      0.480
  PMN conduction velocity, m/s              44.8 ± 4.3     45.6 ± 3.7       44.2 ± 4.6       0.002
  SSN distal latency, m/s                   3.29 ± 0.72    3.19 ± 0.66      3.36 ± 0.75      0.018
  SSN amplitude, mV                         11.6 ± 8.0     11.9 ± 8.2       11.4 ± 8.0       0.560
  SSN conduction velocity, m/s              39.5 ± 11.4    40.0 ± 11.5      39.2 ± 11.3      0.496
  VPT malleolus, mV                         25.9 ± 13.9    25.0 ± 13.7      26.6 ± 14.1      0.262
  VPT hallux, mV                            20.8 ± 13.7    20.0 ± 13.3      21.5 ± 14.0      0.296
  Resting HR, beats/min                     66.9 ± 10.1    69.0 ± 9.3       65.4 ± 10.5      0.001
  HR response to deep breathing, EI ratio   1.24 ± 0.16    1.24 ± 0.15      1.24 ± 0.16      0.818
  HR response to cough test, CT ratio       1.22 ± 0.15    1.20 ± 0.16      1.24 ± 0.15      0.027
  HR response to standing, 30 : 15 ratio    1.14 ± 0.13    1.13 ± 0.12      1.15 ± 0.13      0.105
  SBP response to standing, Δ(mmHg)         4.92 ± 6.48    5.39 ± 6.81      4.56 ± 6.22      0.214
  CVD, *n* (%)                              51 (12.8)      11 (6.4)         40 (17.5)        0.001
  CKD, *n* (%)                                                                               \<0.0001
   No                                       237 (59.3)     100 (58.1)       137 (60.1)       
   Albuminuria alone                        54 (13.5)      13 (7.6)         41 (18.0)        
   Reduced eGFR alone                       68 (17.0)      42 (24.4)        26 (11.4)        
   Both                                     41 (10.2)      17 (9.9)         24 (10.5)        
  DR, *n* (%)                                                                                0.317
   No                                       262 (65.5)     107 (62.2)       155 (68.0)       
   Nonadvanced                              63 (15.7)      27 (15.7)        36 (15.8)        
   Advanced                                 75 (18.8)      38 (22.1)        37 (16.2)        
  DPN, *n* (%)                                                                               \<0.0001
   No                                       117 (29.2)     51 (29.6)        66 (29.0)        
   Polyneuropathy                                                                            
    Possible                                53 (13.2)      28 (16.3)        25 (11.0)        
    Probable                                19 (4.8)       16 (9.3)         3 (1.3)          
    Confirmed                               153 (38.2)     68 (39.5)        85 (37.3)        
    Subclinical                             35 (8.8)       8 (4.7)          27 (11.8)        
   Focal or multifocal neuropathy           15 (3.8)       1 (0.6)          14 (6.1)         
   Diabetes-associated neuropathy           8 (2.0)        0 (0.0)          8 (3.5)          
  CAN, *n* (%)                                                                               0.817
   No                                       267 (66.8)     114 (66.3)       153 (67.1)       
   Borderline                               40 (10.0)      15 (8.7)         25 (11.0)        
   Yes                                      93 (23.2)      43 (25.0)        50 (21.9)        

T1DM = type 1 DM; PA = physical activity; VO~2max~ = maximal oxygen consumption; HbA~1c~ = hemoglobin A~1c~; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; IMT = intima-media thickness; ABI = ankle-brachial index; eGFR = estimated glomerular filtration rate; ACR = albumin : creatinine ratio; PMN peroneal motor nerve; SSN = sural sensory nerve; VPT = vibration perception threshold; HR = heart rate; EI = expiration-to-inspiration; CT = cough test; CVD = cardiovascular disease; CKD = chronic kidney disease; DPN = diabetic peripheral neuropathy; CAN = cardiac autonomic neuropathy.

###### 

QUS values of study subjects, overall and by gender and type of DM.

  QUS parameters   All            Females          Males           *P*        T1DM            T2DM            *P*
  ---------------- -------------- ---------------- --------------- ---------- --------------- --------------- -------
  BUA, dB/MHz      71.6 ± 22.1    62.6 ± 22.1      78.3 ± 19.5     \<0.0001   71.5 ± 24.9     71.6 ± 21.4     0.964
  SOS, m/s         1541 ± 80      1527.3 ± 114.5   1551.8 ± 33.4   0.002      1548.6 ± 38.9   1539.3 ± 87.4   0.354
  QUI              92.0 ± 22.9    84.9 ± 23.1      97.3 ± 21.3     \<0.0001   93.3 ± 25.8     91.6 ± 22.2     0.561
   T-score         −0.80 ± 1.33   −1.06 ± 1.38     −0.61 ± 1.27    0.001      −0.69 ± 1.53    −0.83 ± 1.28    0.376
   Z-score         0.19 ± 1.28    0.25 ± 1.36      0.16 ± 1.24     0.476      −0.10 ± 1.46    0.27 ± 1.23     0.028
  eBMD, g/cm^2^    0.50 ± 0.15    0.45 ± 0.16      0.54 ± 0.13     \<0.0001   0.50 ± 0.19     0.50 ± 0.14     0.915
   T-score         −0.83 ± 1.32   −1.09 ± 1.38     −0.63 ± 1.25    \<0.0001   −0.70 ± 1.53    −0.86 ± 1.27    0.324
   Z-score         0.20 ± 1.28    0.23 ± 1.37      0.18 ± 1.23     0.682      −0.08 ± 1.45    0.27 ± 1.23     0.033

QUS = quantitative ultrasound; DM = diabetes mellitus; T1DM = type 1 DM; T2DM = type 2 DM; BUA = broadband ultrasound attenuation; SOS = speed of sound; QUI = quantitative ultrasound index; eBMD = estimated bone mineral density.

###### 

Univariate correlations between QUS parameters and CVD risk factors and measures of complications (Spearman\'s rho).

  Variable                  BUA      SOS        QUI      eBMD                                    
  ------------------------- -------- ---------- -------- ---------- -------- ---------- -------- ----------
  Age                       −0.176   \<0.0001   −0.261   \<0.0001   −0.232   \<.00001   −0.225   \<0.0001
  Upper body strength       0.287    \<0.0001   0.234    \<0.0001   0.261    \<0.0001   0.259    \<0.0001
  Lower body strength       0.288    \<0.0001   0.252    \<0.0001   0.271    \<0.0001   0.273    \<0.0001
  Vo~2max~                  0.289    \<0.0001   0.242    \<0.0001   0.258    \<0.0001   0.262    \<0.0001
  DM duration               −0.129   0.010      −0.070   0.162      −0.100   0.047      −0.092   0.068
  HbA~1c~                   0.055    0.273      0.104    0.038      0.087    0.083      0.089    0.075
  Glucose                   0.047    0.349      0.048    0.341      0.051    0.310      0.051    0.314
  BMI                       0.194    \<0.0001   0.129    0.010      0.174    \<0.0001   0.174    \<0.0001
  Fat mass                  −0.087   0.084      −0.051   0.315      −0.051   0.307      −0.060   0.229
  Fat-free mass             0.386    \<0.0001   0.278    \<0.0001   0.328    \<0.0001   0.336    \<0.0001
  Waist circumference       0.248    \<0.0001   0.160    0.001      0.212    \<0.0001   0.217    \<0.0001
  Triglycerides             0.162    0.001      0.094    0.060      0.133    0.008      0.137    0.006
  Total cholesterol         −0.053   0.292      −0.019   0.713      −0.027   0.597      −0.028   0.578
  HDL cholesterol           −0.251   \<0.0001   −0.182   \<0.0001   −0.217   \<0.0001   −0.217   \<0.0001
  LDL cholesterol           −0.003   0.947      0.026    0.600      0.019    0.704      0.017    0.736
  SBP                       −0.055   0.274      −0.090   0.073      −0.072   0.151      −0.069   0.169
  DBP                       0.001    0.984      −0.013   0.793      0.001    0.981      0.002    0.975
  Carotid IMT               0.030    0.548      −0.030   0.556      −0.005   0.915      −0.003   0.958
  ABI                       0.084    0.093      0.107    0.034      0.097    0.052      0.093    0.063
  Uric acid                 0.166    0.001      0.112    0.026      0.139    0.005      0.132    0.008
  Plasma nitrogen           −0.056   0.263      −0.078   0.122      −0.085   0.088      −0.072   0.150
  Serum creatinine          0.077    0.126      0.092    0.069      0.086    0.088      0.088    0.082
  eGFR                      0.070    0.161      0.103    0.041      0.102    0.041      0.096    0.057
  ACR                       0.095    0.057      0.115    0.022      0.107    0.033      0.116    0.021
  PMN distal latency        0.069    0.167      0.062    0.215      0.063    0.209      0.075    0.134
  PMN amplitude             0.072    0.150      0.107    0.034      0.101    0.045      0.091    0.068
  PMN conduction velocity   0.015    0.771      0.021    0.684      0.032    0.526      0.019    0.710
  SSN distal latency        0.120    0.017      0.109    0.029      0.113    0.024      0.113    0.025
  SSN amplitude             0.096    0.055      0.133    0.008      0.133    0.008      0.120    0.016
  SSN conduction velocity   0.034    0.494      0.053    0.294      0.060    0.235      0.046    0.358
  VPT malleolus             −0.047   0.346      −0.073   0.144      −0.062   0.218      −0.050   0.318
  VPT hallux                −0.045   0.365      −0.071   0.156      −0.061   0.221      −0.050   0.319
  Resting HR                −0.080   0.109      −0.085   0.090      −0.089   0.075      −0.092   0.067
  EI ratio                  0.056    0.273      0.069    0.175      0.071    0.165      0.069    0.178
  CT ratio                  0.099    0.052      0.123    0.015      0.119    0.019      0.123    0.015
  30 : 15ratio              0.114    0.025      0.181    \<0.0001   0.161    0.001      0.157    0.002
  Systolic BP fall          0.031    0.546      −0.011   0.822      0.005    0.914      0.004    0.938
  BUA                       ---      ---        0.850    \<0.0001   0.935    \<0.0001   0.930    \<0.0001
  SOS                       0.850    \<0.0001   ---      ---        0.973    \<0.0001   0.973    \<0.0001
  QUI                       0.935    \<0.0001   0.973    \<0.0001   ---      ---        0.995    \<0.0001
  eBMD                      0.930    \<0.0001   0.973    \<0.0001   0.995    \<0.0001   ---      ---

QUS = quantitative ultrasound; CVD = cardiovascular disease; BUA = broadband ultrasound attenuation; SOS = speed of sound; QUI = quantitative ultrasound index; eBMD = estimated bone mineral density; DM = diabetes mellitus; VO~2max~ = maximal oxygen consumption; HbA~1c~ = hemoglobin A~1c~; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; IMT = intima-media thickness; ABI = ankle-brachial index; eGFR = estimated glomerular filtration rate; ACR = albumin : creatinine ratio; PMN peroneal motor nerve; SSN = sural sensory nerve; VPT = vibration perception threshold; HR = heart rate; EI = expiration : inspiration; CT = cough test.

###### 

Independent correlates of QUS parameters by multiple regression analysis with stepwise variable selection, in the whole cohort and in patients with T1DM and T2DM separately.

  Variable                                  BUA      SOS        QUI      eBMD                                    
  ----------------------------------------- -------- ---------- -------- ---------- -------- ---------- -------- ----------
  Whole cohort                                                                                                   
  Age                                       −0.284   0.001      −0.344   \<0.0001   −0.342   \<0.0001   −0.236   0.001
  Male gender                               0.356    \<0.0001   0.191    0.011      0.245    0.001      0.244    0.001
  HbA~1c~                                   ---      ---        0.169    0.047      ---      ---        0.148    0.043
  BMI                                       0.290    \<0.0001   0.334    \<0.0001   0.355    \<0.0001   0.299    \<0.0001
  PMN amplitude                             0.153    0.035      0.181    0.018      0.160    0.031      0.190    0.012
  SSN amplitude                             0.228    0.017      0.168    0.028      0.185    0.016      0.180    0.018
  VPT hallux                                ---      ---        0.329    0.009      0.259    0.015      ---      ---
  Resting HR                                ---      ---        −0.192   0.012      ---      ---        −0.196   0.010
  HR response to cough test (CT ratio)                                                                  0.143    0.050
  HR response to standing (30 : 15 ratio)   ---      ---        ---      ---        0.176    0.022      0.139    0.021
  T1DM                                                                                                           
  Age                                       −0.450   0.001      −0.597   \<0.0001   −0.462   0.001      −0.319   0.020
  Male gender                               0.296    0.007      ---      ---        0.230    0.032      0.258    0.019
  HbA~1c~                                   ---      ---        ---      ---        ---      ---        ---      ---
  BMI                                       0.371    0.007      ---      ---        0.288    0.018      0.395    0.002
  PMN amplitude                             0.679    \<0.0001   0.510    0.002      0.547    0.001      0.739    \<0.0001
  SSN amplitude                             0.296    0.041      ---      ---        0.299    0.042      ---      ---
  VPT hallux                                0.502    0.007      0.476    0.023      0.406    0.031      0.410    0.040
  Resting HR                                ---      ---        ---      ---        ---      ---        ---      ---
  HR response to cough test (CT ratio)                                                                  0.251    0.027
  HR response to standing (30 : 15 ratio)   ---      ---        ---      ---        ---      ---        0.246    0.024
  T2DM                                                                                                           
  Age                                       ---      ---        ---      ---        −0.134   0.014      −0.169   0.003
  Male gender                               0.396    \<0.0001   0.218    \<0.0001   0.283    \<0.0001   0.272    \<0.0001
  HbA~1c~                                   0.113    0.029      0.140    0.012      0.136    0.011      0.119    0.030
  BMI                                       0.344    \<0.0001   0.392    \<0.0001   0.414    \<0.0001   0.409    \<0.0001
  PMN amplitude                             0.175    0.048      0.128    0.044      0.205    0.023      0.132    0.034
  SSN amplitude                             ---      ---        0.166    0.011      0.215    \<0.0001   0.163    0.011
  VPT hallux                                ---      ---        ---      ---        ---      ---        ---      ---
  Resting HR                                ---      ---        −0.120   0.032      ---      ---        −0.114   0.037
  HR response to cough test (CT ratio)      ---      ---        0.204    0.019      ---      ---        ---      ---
  HR response to standing (30 : 15 ratio)   ---      ---        ---      ---        ---      ---        ---      ---

QUS = quantitative ultrasound; T1DM = type 1 DM; T2DM = type 2 DM; BUA = broadband ultrasound attenuation; SOS = speed of sound; QUI = quantitative ultrasound index; eBMD = estimated bone mineral density; HbA~1c~ = hemoglobin A~1c~; BMI = body mass index; PMN peroneal motor nerve; SSN = sural sensory nerve; VPT = vibration perception threshold; HR = heart rate.
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